Migoprotafib (GDC-1971) (compound 199) is a SHP2 inhibitor. Migoprotafib inhibits the MAPK/ERK signaling pathway, and exhibits antitumor activity[1][2].
体外研究:
Migoprotafib (60 mg/kg, po for 28 days) 在 RIT1 异种移植小鼠模型中表现出抗肿瘤活性[2]。
参考文献:
1. Alexander M, et al. Shp2 phosphatase inhibitors and methods of use thereof. Patent WO2019183367A1. 2. Maddalo D, et al. RIT1M90I is a driver of lung adenocarcinoma tumorigenesis and resistance to targeted therapy[J]. 2024.